Eli Lilly surpasses Johnson & Johnson with a $445 billion market cap
Eli Lilly (ticker LLY) is now worth $445 billion versus $430 billion for JNJ. Even more interesting is the dividend of these two giants, with Eli Lilly's dividend growing much faster in the last five years.
Many smart dividend investors know that the stock price eventually follows the dividend, so higher dividend growth most of the time also equals a better stock price performance over time. When looking at Johnson & Johnson vs. Eli Lilly this is just the perfect example. Lilly has been on a tear the last couple of years, not only with its dividend, but also with the stock price. This results in this blog post Today with LLY surpassing JNJ's market cap.
|JNJ has been massively outperformed by LLY|
Eli Lilly has a 1103% total return in the last 10 years vs. Johnson & Johnson' 152.8% total return (see chart above). Also Eli Lilly's dividend growth was much better in the last five years with LLY lagging in dividend for a long time before dividend growth picked up with 15% hikes since 2018, beating JNJ with an average 6% hike based on the last five years.
DIVIDEND HIKES JOHNSON & JOHNSON SINCE 2018
- 2023: +5.3%
- 2022: +6.6%
- 2021: +5.0%
- 2020: +6.3%
- 2019: +5.6%
- 2018: +7.1%
- 2023: TBA (expected December 2023)
- 2022: +15.3%
- 2021: +15.3%
- 2020: +14.9%
- 2019: +14.7%
- 2018: +14.7%